ProCE Banner Series

Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors

Join us either in person or virtually for this live, CME-certified symposium featuring an expert discussion of TROP2- and HER3-targeted antibody-drug conjugates and their current use in treating patients with solid tumors, including lung and breast cancers. This activity will feature interactive patient case scenarios and dynamic question and answer sessions. Sign up now!

To Register: Please click the green “Learn More” button below. On the next page, select either “Register for In-Person Event” or “Register for Virtual Event”. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

Clinical Care Options, LLC. is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19.

For more information on AACR’s vaccination and mask requirements, please visit: AACR’s website

This symposium is sponsored by Clinical Care Options, LLC. This is not an official program of the American Association for Cancer Research Annual Meeting. Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

  AMA
Who Should Attend

This program is intended for pathologists, oncologists, pulmonologists, clinical investigators, and other healthcare professionals involved in the treatment of patients with solid tumors.

All Events

Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors

Past Events

April

16

2023

6:30 PM - 9:00 PM Eastern Time (ET)

In-personVirtual

Rosen Centre Hotel, 9840 International Dr., Orlando, Florida 32819

Faculty

ProCE Banner Faculty
Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

ProCE Banner Faculty
Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Paolo Tarantino, MD

Advanced Research Fellow
Harvard Medical School
Department of Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, confidence and competence of learners in the optimal application of current and emerging data with TROP2 and HER3-targeting ADCs in solid tumors.

Target Audience
This program is intended for pathologists, oncologists, pulmonologists, clinical investigators, and other healthcare professionals involved in the treatment of patients with solid tumors.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the biologic rationale for targeting TROP2 and features that differentiate the antibody–drug conjugates targeting TROP2
  • Select TROP2–targeting antibody–drug conjugate therapy or clinical trial enrollment for appropriate patients with NSCLC
  • Develop a treatment plan with agents targeting TROP2 in patients with TNBC or endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer
  • Identify patients with locally advanced or metastatic NSCLC with an EGFR-activating mutation post TKI failure for enrollment on clinical trials investigating HER3-targeted agents
  • Construct a supportive care plan for patients experiencing treatment-related symptoms on treatment with a HER3- or TROP2‒targeted therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.